文献速递母胎医学

黏多糖贮积症VII型的产前诊断促进新生儿期治疗

Prenatal diagnosis of mucopolysaccharidosis type VII facilitating treatment in neonatal period.
PubMed 文献 · Prenat Diagn · 2023-11-14

一例经体外受精供卵受孕胎儿在孕20+0周出现非免疫性胎儿水肿, duo外显子检测发现GUSB基因两个变异,羊水上清生化显示糖胺聚糖升高和β-葡萄糖醛酸苷酶活性降低,确诊黏多糖贮积症VII型。婴儿36+5周出生,20日龄开始vestronidase酶替代治疗,耐受良好,尿糖胺聚糖下降,计划造血干细胞移植。

要点

  • 羊水上清生化检测可辅助判读GUSB基因变异致病性,确诊MPS-VII。
  • MPS-VII是可治的非免疫性胎儿水肿病因,产前诊断有助于新生儿期启动治疗。
  • 本例20日龄开始vestronidase酶替代治疗,耐受良好,长期随访待定。

核心结论

  • 本病例显示替代检测方法有助于明确变异致病性,产前诊断可促进新生儿期治疗。
  • MPS-VII是可治的非免疫性胎儿水肿病因。
  • 长期随访需确定治疗是否成功。

研究设计与样本

  • 对一例经体外受精供卵受孕、孕20+0周出现非免疫性胎儿水肿的胎儿行 duo外显子检测。
  • 羊水上清行生化检测糖胺聚糖和β-葡萄糖醛酸苷酶活性。

主要发现

  • GUSB基因检出两个变异,初始判读一个为可能致病、另一个为临床意义不明。
  • 羊水上清糖胺聚糖升高、β-葡萄糖醛酸苷酶活性降低,符合MPS-VII诊断,两个变异致病性均升级。
  • 婴儿36+5周出生,20日龄开始vestronidase酶替代治疗,耐受良好,尿糖胺聚糖定量下降。
  • 计划造血干细胞移植持续进行中。

关键数值与推荐

  • GUSB双等位基因致病性变异导致MPS-VII,可产前表现为非免疫性胎儿水肿。
  • 羊水上清糖胺聚糖升高和β-葡萄糖醛酸苷酶活性降低支持MPS-VII诊断。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需长期随访以确定治疗是否成功。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Duo exome testing was performed on a fetus conceived via in vitro fertilization with an egg donor. The fetus presented with non-immune hydrops fetalis (NIHF) at 20 + 0 weeks gestation. Two variants were detected in the GUSB gene. Biallelic pathogenic variants cause mucopolysaccharidosis type VII (MPS-VII), which can present with NIHF prenatally. At the time of analysis and initial report, one variant was classified as likely pathogenic and the other as of uncertain clinical significance. Biochemical testing of the amniotic fluid supernatant showed elevated glycosaminoglycans and low β-glucuronidase activity consistent with the diagnosis of MPS-VII. This evidence allowed the upgrade of the pathogenicity for both variants, confirming the diagnosis of MPS-VII. The infant was born at 36 + 5 weeks and enzyme replacement therapy (ERT) using vestronidase was initiated at 20 days with planning for hematopoietic stem cell transplant ongoing. The ERT therapy has been well tolerated, with decreasing quantitative urine glycosaminoglycans. Long-term follow up is required to determine whether treatment has been successful. This case demonstrates the utility of alternative testing methods to clarify the pathogenicity of variants and the clinical utility of obtaining a diagnosis antenatally in facilitating treatment in the neonatal period, and specifically highlights MPS-VII as a treatable cause of NIHF.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Chandler NJ, Ramachandran V, Beesley C, et al. Prenatal diagnosis of mucopolysaccharidosis type VII facilitating treatment in neonatal period. Prenat Diagn. 2023. PMID: 37964423. doi:10.1002/pd.6455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。